Market Overview

UPDATE: JP Morgan Upgrades Thermo Fisher Scientific to Overweight on Favorable Risk/Reward

Share:
Related TMO
The Market In 5 Minutes: Up And Down Week Comes To A Close
Benzinga's M&A Chatter for Thursday August 18, 2016
FDA recommends Zika screening of blood components in all states and territories (Seeking Alpha)

JP Morgan upgraded Thermo Fisher Scientific (NYSE: TMO) from Neutral to Overweight and raised the price target from $70.00 to $80.00.

JP Morgan noted, "We are upgrading Thermo Fisher Scientific (TMO) from Neutral to Overweight on favorable risk/reward due to conservative guidance that should be at worst achievable, and more likely beatable, and an improving record of capital deployment since management has increasingly focused on the higher bar of ROIC, rather than simply adjusted EPS accretion. The company's robust and growing free cash flow provides clear optionality around additional capital deployment, including but not limited to recent press reports (Reuters) that it is now evaluating a purchase of Life Technologies (LIFE)."

Thermo Fisher Scientific closed at $72.14 on Thursday.

Latest Ratings for TMO

DateFirmActionFromTo
Jul 2016CitigroupMaintainsBuy
Jul 2016BTIG ResearchAssumesBuy
Jul 2016BarclaysMaintainsOverweight

View More Analyst Ratings for TMO
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Analyst Ratings

 

Related Articles (TMO)

View Comments and Join the Discussion!